Shares of Evoke Pharma Inc (NASDAQ:EVOK) have been given a consensus rating of “Buy” by the nine research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and six have given a buy recommendation to the company. The average 12-month price objective among brokerages that have issued a report on the stock in the last year is $9.14.
A number of research analysts recently commented on EVOK shares. FBR & Co reaffirmed a “buy” rating and issued a $10.00 price target on shares of Evoke Pharma in a report on Thursday, October 19th. Northland Securities reissued a “buy” rating and issued a $10.00 price objective on shares of Evoke Pharma in a research note on Wednesday, October 18th. HC Wainwright reissued a “buy” rating and issued a $9.00 price objective on shares of Evoke Pharma in a research note on Tuesday, October 24th. Zacks Investment Research raised shares of Evoke Pharma from a “sell” rating to a “hold” rating in a research note on Monday, November 20th. Finally, ValuEngine downgraded shares of Evoke Pharma from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st.
A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Sphera Funds Management LTD. lifted its stake in Evoke Pharma by 34.7% in the fourth quarter. Sphera Funds Management LTD. now owns 769,149 shares of the specialty pharmaceutical company’s stock worth $1,738,000 after purchasing an additional 198,127 shares during the last quarter. Vanguard Group Inc. lifted its stake in Evoke Pharma by 15.1% in the second quarter. Vanguard Group Inc. now owns 523,650 shares of the specialty pharmaceutical company’s stock worth $1,341,000 after purchasing an additional 68,544 shares during the last quarter. B. Riley Financial Inc. bought a new stake in Evoke Pharma in the fourth quarter worth about $249,000. Finally, Creative Planning bought a new stake in shares of Evoke Pharma during the fourth quarter valued at approximately $226,000. 14.29% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY NOTICE: This article was originally published by American Banking News and is the property of of American Banking News. If you are reading this article on another site, it was illegally stolen and republished in violation of U.S. and international trademark & copyright law. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/02/13/evoke-pharma-inc-evok-given-average-recommendation-of-buy-by-analysts.html.
Evoke Pharma Company Profile
Evoke Pharma, Inc is a specialty pharmaceutical company. The Company is focused primarily on the development of drugs to treat gastrointestinal (GI) disorders and diseases. The Company is developing EVK-001, a metoclopramide nasal spray for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in women.
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.